Stock SONN SONNET BIOTHERAPEUTICS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Sonnet BioTherapeutics Holdings, Inc.

Equities

SONN

US83548R3030

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-01 pm EDT 		5-day change 1st Jan Change
1.86 USD +5.08% Intraday chart for Sonnet BioTherapeutics Holdings, Inc. +0.81% +6.90%
Mar. 11 Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street MT
Mar. 11 Top Premarket Gainers MT

Evolution of the average Target Price on Sonnet BioTherapeutics Holdings, Inc.

Price target over the last 5 years

History of analyst recommendation changes

d1f2cef514ba8126c5.cfGEG5I1JDl-b9MYmfXGpfnTNj0F3uClvC4DnW0aqVc.Ccb9VNkAaXAuIr5a8IKu9LujX3M2ma3Q0kt2y14p2T4JnsV69EFpcDBCng~e30b719f21938e16680c72efdade46c8

Analyst Recommendations on Sonnet BioTherapeutics Holdings, Inc.

Chardan Cuts PT on Sonnet BioTherapeutics to $30 From $75 to Reflect Higher Projected Future Share Count, Keeps Buy Rating MT
Ladenburg Thalmann Starts Sonnet BioTherapeutics Holdings With Buy Rating, $7 Price Target MT
EF Hutton Assumes Sonnet BioTherapeutics at Buy With $6.70 Price Target MT
Chardan Cuts Price Target on Sonnet BioTherapeutics to $12 From $14, Keeps Buy Rating MT
EF Hutton Assumes Buy Rating on Sonnet BioTherapeutics With $6.70 Price Target MT
Chardan Lowers Price Target on Sonnet BioTherapeutics to $14 From $17, Keeps Buy Rating MT
Chardan Cuts Price Target on Sonnet BioTherapeutics to $17 From $22, Anticipating Higher Future Share Count, Maintains Buy Rating MT
Health Care Down Sharply on Rate-Sensitive Sector Bias -- Health Care Roundup DJ
EF Hutton Initiates Coverage on Sonnet BioTherapeutics Holdings at Buy With $6.70 Price Target MT
Chardan Adjusts Sonnet BioTherapeutics Holdings Price Target to $22 From $2, Maintains Buy Rating MT
Chardan Trims Sonnet BioTherapeutics Holdings' Price Target to $2 From $2.50, Maintains Buy Rating MT
Wall Street Set for Gains Ahead of Fed's Rate Decision MT
BTIG Adjusts Price Target on Sonnet BioTherapeutics Holdings to $2 From $5, Reiterates Buy Rating MT
Chardan Capital Adjusts Sonnet BioTherapeutics Holdings PT to $2.50 From $8, Maintains Buy Rating MT
HC Wainwright Initiates Coverage on Sonnet BioTherapeutics Holdings With Buy Rating, $2 Price Target MT
SONNET BIOTHERAPEUTICS : BTIG Starts Sonnet BioTherapeutics Holdings at Buy with $5 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.86 USD
Average target price
12.5 USD
Spread / Average Target
+572.04%
High Price Target
30 USD
Spread / Highest target
+1,512.90%
Low Price Target
2 USD
Spread / Lowest Target
+7.53%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Sonnet BioTherapeutics Holdings, Inc.

Chardan Research
Ladenburg Thalmann
EF Hutton
BTIG
Chardan
HC Wainwright

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. SONN Stock
  4. Consensus Sonnet BioTherapeutics Holdings, Inc.